TB-500
Thymosin Beta-4 Synthetic Fragment
Evidence & Status
- Preliminary / Experimental
- Preliminary
At a Glance
A synthetic heptapeptide corresponding to the actin-binding motif LKKTETQ (residues 17–23 of thymosin beta-4). This record covers the LKKTETQ fragment only — not full-length thymosin beta-4, which is a distinct 43-amino-acid protein. Studied in preclinical models for wound healing, anti-inflammatory, and tissue repair effects.
Plain English
TB-500 refers to the seven-amino-acid LKKTETQ fragment derived from the actin-binding region of the larger thymosin beta-4 protein. It is not the same molecule as full-length thymosin beta-4. Researchers study this fragment because the LKKTETQ sequence appears to coordinate cellular repair processes in preclinical models — including cell migration, new blood vessel formation, and inflammation modulation. Most foundational research has been conducted in animal models. No adequate human interventional evidence specific to the LKKTETQ fragment was identified in this review.
Overview
TB-500 is identified by FDA as the N-terminally acetylated seven-amino-acid fragment Ac-LKKTETQ (free base; UNII QHK6Z47GTG, CAS 885340-08-9), characterized in the July 2026 FDA Pharmacy Compounding Advisory Committee briefing document with a molecular weight of 889.01 g/mol. This free-base form is distinct from TB-500 acetate (C₃₈H₆₈N₁₀O₁₄·CH₃COOH, MW 949.1 g/mol) and from full-length 43-amino-acid thymosin beta-4. Evidence and human trials of full-length thymosin beta-4 must not be transferred to this distinct fragment.
Research Summary
No adequate human interventional evidence specific to the LKKTETQ fragment was identified in this review. Full-length thymosin beta-4 research is an entity mismatch and is excluded from this record. A July 2026 Pharmacy Compounding Advisory Committee discussion was advisory only and does not constitute FDA approval or a final FDA determination.
Research Areas
- Muscle repair
- Angiogenesis
- Inflammation
- Cardiac repair
- Wound healing
Safety & Risks
Serious Risks
- Human safety, pharmacokinetics, and long-term outcomes for the LKKTETQ fragment have not been established
Reported Side Effects
- Injection site discomfort
- Temporary fatigue
- Headache (rare)
Legal Status by Region
- United States
- Not FDA approved. The HHS interim 503A policy describes conditional enforcement discretion for TB-500 acetate in subcutaneous or intramuscular injectable dosage forms. It does not cover the free-base fragment identified in this profile or full-length thymosin beta-4 by inference. This is not proof of safety or effectiveness or blanket compounding legality. The Federal Register notice describes a draft, nonbinding policy; no effective date is asserted here. Conditions include a patient-specific prescription; a State-licensed pharmacy, Federal facility or licensed physician; the exact Appendix B identity and route; FDA-registered original API manufacture compliant with CGMP, valid COAs, required quality testing and supplier validation; reporting compounded products, serious adverse events and quality issues to FDA and relevant States; patient reporting instructions and labeling 'This is a compounded drug product. Not for resale.'; a single Appendix A active ingredient; only a 510(k)-cleared syringe if a delivery device is co-packaged or contains the drug; and all other applicable FD&C Act requirements. This is not a 503B authorization. The interim policy lasts until a final rule addresses the substance and may be revisited for safety or quality signals.
- United Kingdom
- Research only
- Australia
- Research only
- Canada
- Research only
Citations & Sources
- TB-500 (Ac-LKKTETQ free base) — FDA Substance Registration, UNII QHK6Z47GTG; molecular identity characterized in July 2026 FDA Pharmacy Compounding Advisory Committee briefing document
2026
Regulatory UNII QHK6Z47GTG
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, including Appendices A and B
U.S. Department of Health and Human Services · HHS
- Public inspection notice: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (filed October 28, 2026; scheduled publication October 30, 2026; not an effective-date determination)
U.S. Department of Health and Human Services · Federal Register — Public Inspection
Regulatory FR Doc. 2026-22192